Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results.

Mul D, Bertelloni S, Carel JC, Saggese G, Chaussain JL, Oostdijk W

Hormone research1 Jan 2002Cited by 33 (Europe PMC)

PMID12169774DOI10.1159/000063209PepBankPUB-12169774

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In boys with central precocious puberty treated with triptorelin, final height was 172.9 +/- 6.6 cm.
In plain wordsIn boys with early puberty treated with triptorelin, final height was 172.9 cm.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableFinal height
Study
n = 26
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 4.7 +/- 2.1 yearsAs given in this study (human).
Measurements
Final height
172.9 cm
treated boys
Source sentences
Summary
FH was 172.9 +/- 6.6 cm.
2 context sentences(design, population, supporting numbers)
Summary · context
We therefore combined FH data from The Netherlands, Italy and France to study the effect of GnRHa treatment in a large group of 26 boys with CPP.
Summary · context
All boys were treated with depot formulations of the GnRHa triptorelin with established gonadal suppression for a mean treatment period of 4.7 +/- 2.1 years.
Report a problemFND-1216977401
02HumanObservational studyEfficacy outcome
In treated boys, final height SDS did not differ significantly from target height SDS.
In plain wordsIn treated boys, final height scores did not differ significantly from target height scores.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFinal height SDS versus target
Study
n = 26
Comparator
Target height SDS
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 4.7 +/- 2.1 yearsAs given in this study (human).
Measurements
Final height SDS
−0.66 SDS
treated boys
Target height SDS
−0.23 SDS
target
Source sentences
Summary
FH standard deviation score (SDS) was -0.66 +/- 1.22, not significantly different from the target height SDS of -0.23 +/- 0.75.
2 context sentences(design, population, supporting numbers)
Summary · context
We therefore combined FH data from The Netherlands, Italy and France to study the effect of GnRHa treatment in a large group of 26 boys with CPP.
Summary · context
All boys were treated with depot formulations of the GnRHa triptorelin with established gonadal suppression for a mean treatment period of 4.7 +/- 2.1 years.
Report a problemFND-1216977402
03HumanObservational studyEfficacy outcome
In treated boys, estimated height gain using average Bayley and Pinneau tables was 6.2 +/- 8.7 cm.
In plain wordsIn treated boys, height gain relative to average-table predictions was 6.2 cm.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseEstimated height gain using average tables
Study
n = 26
Comparator
Predicted adult height using average Bayley and Pinneau tables
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 4.7 +/- 2.1 yearsAs given in this study (human).
Measurements
Estimated height gain
6.2 cm
average tables
Source sentences
Summary
The mean estimated height gain, defined as the difference between predicted and actual adult height was 6.2 +/- 8.7 cm using the average tables of Bayley and Pinneau, and 0.3 +/- 8.6 cm using the BA advance adjusted tables.
2 context sentences(design, population, supporting numbers)
Summary · context
We therefore combined FH data from The Netherlands, Italy and France to study the effect of GnRHa treatment in a large group of 26 boys with CPP.
Summary · context
All boys were treated with depot formulations of the GnRHa triptorelin with established gonadal suppression for a mean treatment period of 4.7 +/- 2.1 years.
Report a problemFND-1216977403
04HumanObservational studyEfficacy outcome
In boys with central precocious puberty treated with triptorelin, mean estimated height gain was 6.2 +/- 8.7 cm using average Bayley and Pinneau tables and 0.3 +/- 8.6 cm using bone-age-advance adjusted tables.
In plain wordsIn 26 boys with early puberty given triptorelin, estimated height gain was 6.2 cm with one table method and 0.3 cm with another.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedEstimated height gain (predicted minus actual adult height)
Study
n = 26
Comparator
Predicted adult height from Bayley and Pinneau tables
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 4.7 +/- 2.1 yearsAs given in this study (human).
Measurements
Estimated height gain
6.2 cm
average tables of Bayley and Pinneau
Estimated height gain
0.3 cm
BA advance adjusted tables
Source sentences
Summary
The mean estimated height gain, defined as the difference between predicted and actual adult height was 6.2 +/- 8.7 cm using the average tables of Bayley and Pinneau, and 0.3 +/- 8.6 cm using the BA advance adjusted tables.
2 context sentences(design, population, supporting numbers)
Summary · context
We therefore combined FH data from The Netherlands, Italy and France to study the effect of GnRHa treatment in a large group of 26 boys with CPP.
Summary · context
All boys were treated with depot formulations of the GnRHa triptorelin with established gonadal suppression for a mean treatment period of 4.7 +/- 2.1 years.
Report a problemFND-1216977404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.